Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017136770) TREATMENT OF HER2-INTERMEDIATE CANCER
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/136770 International Application No.: PCT/US2017/016576
Publication Date: 10.08.2017 International Filing Date: 03.02.2017
IPC:
A61K 9/127 (2006.01) ,A61K 31/704 (2006.01) ,A61K 39/395 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
10
Dispersions; Emulsions
127
Liposomes
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
70
Carbohydrates; Sugars; Derivatives thereof
7028
Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
7034
attached to a carbocyclic compound, e.g. phloridzin
704
attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Applicants:
MERRIMACK PHARMACEUTICALS, INC. [US/US]; One Kendall Square Suite B7201 Cambridge, Massachusetts 02139-1670, US
Inventors:
DUMONT, Nancy; US
ESPELIN, Christopher, W.; US
GERETTI, Elena; US
MOLNAR, Istvan; US
MOYO, Victor; US
REYNOLDS, Joseph G.; US
WICKHAM, Thomas; US
Agent:
ALBERDI, Fernando; US
Priority Data:
62/291,80205.02.2016US
62/323,54515.04.2016US
62/362,25314.07.2016US
62/405,62607.10.2016US
Title (EN) TREATMENT OF HER2-INTERMEDIATE CANCER
(FR) TRAITEMENT DE CANCERS À NIVEAU INTERMÉDIAIRE DE HER2
Abstract:
(EN) Patients with gastric cancer or breast cancer, for example, metastatic breast cancer can be treated with doxorubicin encapsulated in a MM-302 HER-2 targeted immunoliposome, including patients with breast cancer characterized as HER-2 intermediate (e.g., having breast cancer or metastatic breast cancer, wherein each of the breast cancer or metastatic breast cancers are characterized by a HER2 IHC score of 1+ or 2+ with a FISH negative score, or alternatively are FISH negative, or alternatively, are characterized by HER2 IHC score of 1+ and FISH negative, or alternatively, the breast cancer or metastatic breast cancers are characterized by HER2 IHC score of 2+ and FISH negative, or alternatively, the breast cancer or metastatic breast cancers are characterized by a HER2 IHC score of 1+ and are FISH positive, or characterized by HER2 IHC score of 2+ and are FISH positive.
(FR) Selon la présente invention, les patients atteints de cancer gastrique ou de cancer du sein, par exemple de cancer du sein métastatique, peuvent être traités par de la doxorubicine encapsulée dans un immunoliposome conçu pour cibler HER-2, MM-302, cela comprenant des patients atteints d'un cancer du sein caractérisé comme étant d'un niveau intermédiaire pour HER-2 (par exemple, atteints d'un cancer du sein ou d'un cancer du sein métastatique, lesquels cancer du sein ou cancers du sein métastatiques sont chacun caractérisés par un score HER2 de 1+ ou 2+ en IHC associé à un score négatif en FISH, ou alternativement sont négatifs en FISH, ou, alternativement, sont caractérisés par un score HER2 de +1 en IHC et sont négatifs en FISH, ou, alternativement, le cancer du sein ou les cancers du sein métastatiques sont caractérisés par un score HER2 de +2 en IHC et sont négatifs en FISH, ou, alternativement, le cancer du sein ou les cancers du sein métastatiques sont caractérisés par un score HER2 de +1 en IHC et sont positifs en FISH, ou sont caractérisés par un score HER2 de +2 en IHC et sont positifs en FISH.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)